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The endogenous opioid peptides dynorphins and enkephalins may be involved in
brain-area specific synaptic adaptations relevant for different stages of an addiction cycle.
We compared the levels of prodynorphin (PDYN) and proenkephalin (PENK) mRNAs
(by qRT-PCR), and dynorphins and enkephalins (by radioimmunoassay) in the caudate
nucleus and putamen between alcoholics and control subjects. We also evaluated
whether PDYN promoter variant rs1997794 associated with alcoholism affects PDYN
expression. Postmortem specimens obtained from 24 alcoholics and 26 controls were
included in final statistical analysis. PDYNmRNA and Met-enkephalin-Arg-Phe, a marker
of PENK were downregulated in the caudate of alcoholics, while PDYN mRNA and
Leu-enkephalin-Arg, a marker of PDYN were decreased in the putamen of alcoholics
carrying high risk rs1997794 C allele. Downregulation of opioid peptides in the dorsal
striatum may contribute to development of alcoholism including changes in goal directed
behavior and formation of a compulsive habit in alcoholics.
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Introduction
The endogenous opioid peptides dynorphins and enkephalins and their receptors have a critical
role in drug and alcohol dependence (Shippenberg et al., 2007; Wee and Koob, 2010; Butelman
et al., 2012). In clinics, the opioid antagonist naltrexone reduces alcohol drinking and relapse
rates in subgroups of alcoholics (Volpicelli et al., 1992; Anton, 2008). In animal experiments,
antagonists of the opioid receptors or genetic deletion of these receptors alter alcohol consumption
(Shippenberg et al., 2007; Walker and Koob, 2008; Wee and Koob, 2010). Animal studies
propose that drug/alcohol induced changes in prodynorphin (PDYN) and proenkephalin (PENK)
expression underlie neuroplastic adaptations critical for addiction (Shippenberg et al., 2007;Walker
and Koob, 2008; Wee and Koob, 2010; Butelman et al., 2012). These changes may be brain-area
specific, and may differentially contribute to specific stages of an addiction cycle (Yuferov et al.,
2009; Butelman et al., 2012; Bazov et al., 2013).
Development of drug/alcohol dependence may be viewed as a maladaptive habit formation
during transition from recreational to compulsive use that is associated with a diminishing
cognitive control over drug seeking and taking behavior (Everitt and Robbins, 2005;
Sarkisyan et al. PDYN downregulation in putamen of alcoholics
Shippenberg et al., 2007; Wee and Koob, 2010; Robison and
Nestler, 2011; Butelman et al., 2012). These processes are
characterized by a shift from prefrontal cortical to striatal control
over drug/alcohol use, and a progression from the ventral to
dorsal striatum in the addicted brain (Everitt and Robbins, 2005;
Vollstadt-Klein et al., 2010). Molecular adaptations developed
over the course of drug and alcohol exposure in the dorsal
striatum may be critical for the formation of a compulsive habit
(Belin et al., 2009).
Striatal subregions may be differentially involved in addiction
cycle (Everitt and Robbins, 2005; Balleine and O’Doherty,
2010; Vollstadt-Klein et al., 2010; Butelman et al., 2012). The
caudate nucleus participates in control of goal-directed actions,
and thus may influence goal-directed alcohol seeking. The
putamen has key roles in habit formation, and may participate
in the development of habitual alcohol use. Animal research
demonstrated that the drugs- or alcohol-induced changes in
PDYN and PENK expression in the dorsal striatum may
contribute to the development of addictive state (Spangler et al.,
1993; Shippenberg et al., 2007; Walker and Koob, 2008; Wee and
Koob, 2010; Butelman et al., 2012).
The aim of the present study was to examine whether PDYN
and PENK and their peptide products are involved in adaptive
processes in the dorsal striatum in human alcohol dependent
individuals. We compared the levels of PDYN and PENK mRNA
and four opioid peptides in post-mortem human specimens
from human alcoholics and control subjects. Dynorphin A
(Dyn A), dynorphin B (Dyn B) and Leu-enkephalin-Arg (LER)
derived from PDYN, and Met-enkephalin-Arg-Phe (MEAP)
derived from PENK were analyzed. PENK is processed to
Met-enkephalin and Leu-enkephalin in a 4:1 ratio, as well
as MEAP and Met-enkephalin-Arg-Gly-Leu (Akil et al., 1984;
Christensson-Nylander et al., 1985; Evans et al., 1985; Nyberg
et al., 1986; Nylander et al., 1994; Yakovleva et al., 2006;
Slominski et al., 2011) (http://www.uniprot.org/uniprot/P01210).
The opioid peptide sequences in PDYN are all Leu-enkephalin
with C-terminal extension with an arginine residue. This
sequence is also unique to this prohormone (Christensson-
Nylander et al., 1985; Nyberg et al., 1986; Nylander et al., 1994)
(http://www.uniprot.org/uniprot/P01213) while Leu-enkephalin
is extended from the C-terminus with Lys in PENK. In previous
studies MEAP is measured as a marker of PENK, while Dyn A,
Dyn B and LER as markers of the PDYN system (Christensson-
Nylander et al., 1985; Evans et al., 1985; Nyberg et al., 1986;
Nylander et al., 1994; Yakovleva et al., 2006; Slominski et al.,
2011).
Dyn A and Dyn B function as ligands for κ-opioid receptor
(KOR), whereas LER is potent agonist for δ- (DOR) and µ-
(MOR) opioid receptors and MEAP may activate κ- and µ-
opioid receptors (Christensson-Nylander et al., 1985; Iyengar
et al., 1987; Kamei et al., 1994; Mansour et al., 1995; Benyhe et al.,
1997; Nylander et al., 1997). Single nucleotide polymorphism
(SNP; rs1997794) in PDYN promoter was found to be associated
with alcohol and cocaine dependence (Xuei et al., 2006; Yuferov
et al., 2009) and heroin addiction (Clarke et al., 2009). The C,
high risk allele of this SNP destroys binding element for AP-1
transcription factor and may affect PDYN transcript abundance
in human brain (Babbitt et al., 2010; Taqi et al., 2011). Therefore,
we here evaluated whether this SNP impacts changes in striatal
PDYN expression associated with alcoholism.
Materials and Methods
Human Samples/Case Selection
Tissues were collected at the New South Wales Tissue Resource
Centre (NSW TRC), University of Sydney, Australia (http://
www.braindonors.org; http://rp-host.www.pathology.med.usyd.
edu.au/trc/index.php) (Sheedy et al., 2008). Analysis was initiated
with 30 controls and 30 chronic alcoholics with known
smoking history (Tables 1, 2). All subjects were males of
European descent. Alcohol dependent subjects fulfilled criteria
for Diagnostic and Statistical Manual for Mental Disorders, 4th
edition (DSM-IV) and National Health and Medical Research
Council/World Health Organization Criteria, and consumed
greater than 80 g of ethanol per day for the majority of their adult
lives (Harper et al., 1988). Controls either did not drink alcohol at
all or were social drinkers who consumed less than 20 g of ethanol
per day on average. Control cases were matched to alcoholic
cases by sex, race, age, brain pH and post-mortem interval (PMI).
Cases with a history of polydrug abuse (with evidence that the
individual abused other drugs such as cocaine or heroin) or with
medical complications such as Wernicke-Korsakoff syndrome
or alcoholic cases with concomitant diseases were excluded.
Cases with a prolonged agonal life support or cases with a
history of cerebral infarction, head injury, or neurodegenerative
diseases (e.g., Alzheimer’s disease) were also excluded. Samples
were handled by qualified pathologists under ethical clearance
from Sydney South West Area Health Service, Human Ethics
Committee (X03-0074). Informed written consent was obtained
from the next of kin. The study was approved by the Swedish
Central Ethical Review Board.
Gene Expression Analysis by qRT-PCR
Total RNA Isolation and cDNA Synthesis
Total RNA was purified with RNeasy Lipid Tissue Mini kit
(QIAGEN, Maryland, USA) using TRIzol Reagent (QIAGEN,
Maryland, USA) and treated with RNase-free DNase I on-
column. RNA Quality Indicator (RQI) was measured using
Bio-Rad Experion system (Bio-Rad Laboratories, Hercules,
CA) with Eukaryote Total RNA StdSens assay according to
the manufacturer’s protocol. RNA samples with RQI values
above 5.0 are generally considered suitable for quantitative
real-time polymerase chain reaction (qRT-PCR) (Fleige and
Pfaﬄ, 2006; Fleige et al., 2006). Average values of RQI in
controls and alcoholics were 7.39 ± 1.27 and 7.23 ± 1.41
respectively, demonstrating high quality of isolated RNA. Reverse
transcription of total RNA was performed with cDNA iScript kit
(Bio-Rad Laboratories, Hercules, CA, USA) using CFX96™ Real-
Time Detection System (Bio-Rad Laboratories, Hercules, CA,
USA) according to the manufacturer’s protocol.
Quantitative Real-Time PCR (qRT-PCR)
qRT-PCR was performed on CFX96TM Real-Time Detection
System (Bio-Rad Laboratories, Hercules, CA). For SYBR Green-
based assays, the reaction mixture consisted of cDNA, 5 × HOT
FIREPol R© EvaGreen R© qPCR Mix Plus (Solis BioDyne, Tartu,
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TABLE 1 | Demographic data and tissue characteristics of control
subjects.
Subject Age PMI Brain Storage RQI Smoking
no (years) (hours) pH time history
(months)
1* 54 29 6.8 68 7.3 No
2* 60 13 6.59 168 8.9 NA
3* 53 27 6.64 48 7.7 NA
4* 43 66 6.2 82 6 NA
5* 82 23.5 6.4 92 5.9 NA
6* 68 45.5 6.12 23 6 No
7* 61 27.5 6.25 29 5.5 No
8 50 19 6.26 102 7.8 Yes
9* 57 18 6.6 79 7.8 Yes
10* 54 28 6.38 12 8.3 Yes
11* 53 16 6.5 9 8.9 Yes
12 63 72 6.9 82 8.1 Yes
13* 56 37 6.76 84 8.2 Yes
14* 73 51 6.82 49 4 Yes
15 60 25 6.7 74 6 No
16* 36 34 6.67 13 5.9 Yes
17* 58 28 5.92 11 5.7 Yes
18* 69 52 6.95 9 8.6 No
19* 37 14.5 6.46 9 7.7 No
20 59 40 6.53 22 6.4 Yes
21* 50 30 6.37 22 7.2 Yes
22* 69 16 6.6 80 8.2 Yes
23* 46 25 6.65 119 8.5 NA
24* 60 21.5 6.66 41 7.8 No
25* 73 38.5 6.28 19 8.1 Yes
26* 55 20 6.5 174 8.6 Yes
27* 59 43 6.69 34 8.4 Yes
28* 64 9.5 6.94 49 8.3 Yes
29* 47 38 6.74 24 8.6 Yes
30* 63 24 6.94 52 7.3 Yes
Mean ± 57.7 ± 9.2 31.1 ± 14.8 6.56 ± 0.25 56.0 ± 43.7 7.4 ± 1.2
SD
Mean* ± 57.7 ± 10.7 29.8 ± 13.3 6.6 ± 0.26 53.8 ± 45.2 7.4 ± 1.3
SD*
*Subjects included in the final statistical analysis.
Estonia) and forward and reverse primers (Supplementary Table
S2). The following conditions were applied for the three-step
qRT-PCR reaction; 95◦C for 15min followed by 40 cycles of
amplification at 95◦C for 15 s, annealing temperature for 61.6◦C
for 20 s and elongation at 70◦C for 20 s. Melting curves were
analyzed to ensure primer specificity and lack of primer dimers.
To ensure correct amplification, PCR products were separated
on agarose gel and sequenced in both directions. Samples
were analyzed in triplicates. Using the previously developed
approach for analysis of reference genes (Johansson et al., 2007),
the beta-actin (ACTB), TATA box binding protein (TBP) and
beta-2 microglobulin (B2M) for putamen; and the beta-actin
TABLE 2 | Demographic data and tissue characteristics of alcohol
dependent subjects.
Subject Age PMI Brain Storage RQI Smoking
no (years) (hours) pH time history
(months)
1* 43 29 6.29 56 6.2 Yes
2* 70 32 6.05 143 6.7 NA
3 37 17 6.33 115 6.6 No
4 81 36 6.44 103 8.7 Yes
5* 50 24 6.59 130 8.4 Yes
6* 57 43 6.46 48 8.6 Yes
7* 56 65 6.47 17 5.9 Yes
8* 58 20 6.64 59 6.8 Yes
9* 60 16.5 6.48 46 8.6 Yes
10* 60 51 6.7 66 7.3 No
11* 61 27.5 5.87 19 5.3 Yes
12* 55 48 7.02 25 8.6 Yes
13 41 54 6.7 86 8.2 Yes
14* 53 60 6.75 86 7.6 Yes
15* 63 25.5 6.21 31 5 Yes
16* 73 43.5 6.59 39 7 No
17* 55 17 6.85 22 8.5 No
18* 69 22 5.82 11 5.7 Yes
19 70 62 6.82 92 7.1 Yes
20 65 72 6.88 14 7.1 Yes
21* 58 44.5 6.47 15 8.2 Yes
22* 50 17 6.3 100 6.4 NA
23* 56 15 6.66 113 7.8 NA
24* 59 24 6.57 116 6.6 No
25* 52 45.5 6.78 90 5.8 Yes
26* 70 33.5 6.24 120 3.3 Yes
27 54 17 6.41 142 8.3 Yes
28* 56 22 6.52 116 8.3 Yes
29* 42 41 6.5 82 7.7 No
30* 64 39 6.76 23 9 Yes
Mean ± 57.9 ± 9.8 35.5 ± 16.2 6.5 ± 0.28 70.8 ± 42.3 7.2 ± 1.3
SD
Mean* ± 57.9 ± 7.7 33.6 ± 13.9 6.5 ± 0.29 65.5 ± 41.4 7.1 ± 1.4
SD*
*Subjects included in the final statistical analysis.
(ACTB), TATA box binding protein (TBP) and glyceraldehyde-3-
phosphate dehydrogenase (GAPD) for caudate nucleus were used
for normalization. No fluorescence was observed in samples not
containing template cDNA (no template control) or in negative
controls prepared by the omission of reverse transcriptase.
DNA Purification and Genotyping
DNA was purified from human brain samples using Wizard
Genomic DNA Purification kit (Promega, Madison, USA).
Genotyping of SNP rs1997794 located in PDYN promoter
was performed by allelic discrimination using TaqMan SNP
Genotyping Assay C_11670951_10 (Applied Biosystems, Foster
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City, CA, USA) according to the manufacturer’s protocol.
Polymerase chain reactions were set up in a total volume of
10µl, including 1 × iTaq Universal Probes Supermix (Bio-Rad,
Sunnyvale, CA, USA), 1 × TaqMan SNP Genotyping Assay
(Applied Biosystems), and 10 ng of template DNA using the
BioRad C1000 Thermal Cycler (CFX96 Real-Time System) (Bio-
Rad). After an initial denaturation step for 10min at 95◦C, each
cycle consisted of denaturation for 15 s at 95◦C and annealing
and primer extension for 60 s at 62◦C for a total 40 cycles. The
rs1997794 variant pattern was set up with DNA from positive
controls previously genotyped (Taqi et al., 2011).
Radioimmunoassay (RIA)
The procedure has been described elsewhere (Christensson-
Nylander et al., 1985; Merg et al., 2006). Briefly, 1M hot acetic
acid was added to finely powdered frozen brain tissues, and
samples were boiled for 5min, ultrasonicated and centrifuged.
Tissue extracts were run through SP-Sephadex ion exchange
C-25 column, and peptides were eluted and analyzed by RIA.
Anti-Dyn A antibody demonstrated 100% molar cross-reactivity
with Dyn A (9–17) and <0.1% molar cross-reactivity with
Dyn B, Dyn A (1–8), α-neoendorphin, Leu-enkephalin, and big
dynorphin. Anti-Dyn B antiserum showed 100% molar cross-
reactivity with big dynorphin, 0.8% molar cross-reactivity with
Leu-morphine (29 amino acid C-terminally extended Dyn B),
and <0.1% molar crossreactivity with Dyn A (1–17), Dyn A
(1–8), α-neoendorphin, and Leu-enkephalin (Yakovleva et al.,
2006). Cross-reactivity of LER antiserum with Dyn A, Dyn
B and Leu- and Met-enkephalin was <0.1% molar, with α-
neoendorphin 0.5% molar, with Dyn A (1–8) 0.7% molar, with
MEAP 1% molar and with Met-enkephalin-Arg 10% molar.
Cross-reactivity of MEAP antiserum with Met-enkephalin, Met-
enkephalin-Arg, Met-enkephalin-Arg-Gly-Leu, Leu-enkephalin
and LER was <0.1% molar (Nylander et al., 1997).
Dyn A, Dyn B, and LER RIA readily detected these peptides in
the striatum, hippocampus, and frontal cerebral cortex of wild-
type mice (Nguyen et al., 2005) but not in Pdyn knockout mice
(for details, see Merg et al., 2006); thus the assay was highly
specific and not sensitive to the presence of contaminants in brain
tissues. Protein concentrations were estimated by DC protein
assay (Bio-Rad, Laboratories, Hercules, CA, USA). The peptide
content was calculated with the GraphPad Prism (GraphPad
Software Inc., San Diego, CA, USA) and presented in fmol/mg
of tissue.
Statistical Analyses
Statistical analysis was carried out using the R statistical
software (http://www.R-project.org/) libraries car and lsmeans.
The assumption of conducting analyses of variance (ANOVAs
and ANCOVAs) were verified: (i) residuals being normally
distributed according to Kolmogorov-Smirnov test, and (ii)
error variance being homoscedastic across groups according to
Levene test. Dependent variables (DVs) that failed assumptions
(i) or (ii) were analyzed by Kruskal-Wallis one-way non-
parametric ANOVA. Analyses were conducted in four general
steps. First, data was subjected to one-way ANOVAs with group
as between factor for each of 12 DVs (6molecular levels including
PDYN and PENK mRNA, Dyn A, Dyn B, LER, and MEAP,
in 2 brain regions). Second, we have used backward stepwise
regression to refine the model by determining the relative
importance of each predictor and its statistical significance. The
predictors were selected among demographic parameters and
tissue characteristics group (two levels: controls and alcoholics),
genotype for PDYN system only (two levels: the CC and CT
genotypes vs. the TT genotype of PDYN rs1997794), smoking
(two levels: smokers and non-smokers), age, brain pH, PMI, and
RQI (for mRNA DVs only). Because, an equation containing an
excessive number of independent variables may be overfitted, we
applied a rule of thumb (six cases per variable) to determine
the number of independent variables in the analysis. Library
Hmisc and Bonferroni correction for multiple tests were used to
compute significance of Spearman correlations for demographic
parameters (age, smoking) and tissue characteristics (PMI, pH,
RQI) to ensure that the regression’s predictors were not collinear.
Original models for backward stepwise regressions always
controlled for demographic parameters and tissue characteristics.
When final models showed significant main effect of smoking
or significant group × smoking interaction only subjects with
known smoking history were analyzed. According to the general
approach developed for identification of overly influential points
(Faraway, 2002) we identified 10 subjects (4 controls and 6
alcoholics) with Cook’s distances >1, and each of these ten was
identified as such in two or more regressions. We excluded
these subjects from further analysis because of high likelihood
of them belonging to different subpopulations, or of their
tissue characteristics being heavily influenced by post-mortem
procedures. This resulted in Cook’s distances <0.42 for the
linear models involving remaining 50 subjects. Third, analyses
of covariance (One-Way ANCOVA) with group as between
factor were performed. Fourth, data was subjected to Two-
Way ANCOVAs with group and genotype as between factors.
ANCOVAs were followed by post-hoc pairwise two-way Student’s
t-tests on least squares means (between group and genotype
factors, controlled for confounds) with Sidak correction for
multiple comparisons. A p-value of 0.05 after multiple testing
corrections was accepted as statistically significant.
Results
Analyzing demographic and clinical data and tissue
characteristics t-test showed no significant differences in
age [t(45) = 0.084, p = 0.93], post-mortem interval (PMI)
[t(47) = 0.95, p = 0.35], brain pH values [t(46) = −0.91,
p = 0.37], RNA quality indicator (RQI) [t(46) = −0.99,
p = 0.32] and Firsher’s exact test showed no significant
difference in number of smokers (odd ratio = 0.78, p = 1)
between alcoholics and controls.
To examine whether the endogenous opioid peptide system
undergoes adaptive changes in the striatum of human alcoholics
we analyzed the levels of PDYN and PENK mRNA, PDYN-
derived Dyn A, Dyn B and LER, and PENK-derived MEAP in
post-mortem samples of the caudate and putamen of alcoholics
(24 subjects) and controls (26 subjects).
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For the caudate nucleus, One-Way ANCOVAs revealed effect
of alcoholism on PDYN mRNA [F(1, 36) = 7.6, p = 0.009]
and MEAP [F(1, 40) = 6.85, p = 0.013]. Post-hoc t-test showed
downregulation of PDYN (1.7-fold; p = 0.003) and MEAP (1.5-
fold; p = 0.013) in alcoholics (Figure 1A). PMI [F(1, 36) = 6.7,
p = 0.013] and smoking [F(1, 36) = 4.6, p = 0.039] effects were
revealed for PDYN.
For the putamen, One-Way ANCOVAs revealed effect of
alcoholism on PDYN mRNA [F(1, 35) = 7.3, p = 0.011], Dyn
A [F(1, 39) = 5.3, p = 0.027] and LER [F(1,40) = 10.3, p =
0.003]. Post-hoc t-test showed downregulation of PDYN (1.7-
fold; p = 0.051), Dyn A (1.8-fold; p = 0.027) and LER (1.9-fold;
p = 0.006) in alcoholics (Figure 1B). A pH effect was revealed for
PDYN [F(1, 35) = 5.6, p = 0.024]. Group× smoking interactions
were revealed for PDYN [F(1, 35) = 5.6, p = 0.024] and LER
[F(1, 35) = 6.5, p = 0.015].
PDYN promoter SNP (rs1997794) associated with alcoholism
(Xuei et al., 2006; Yuferov et al., 2009) may form non-canonical
AP-1 binding site and influence gene expression in human brain
(Taqi et al., 2011). We next examined whether adaptive PDYN
responses to alcohol are modulated by this SNP. The Fisher’s
exact test revealed no significant differences in distribution of the
promoter SNP rs1997794 genotypes (p = 0.24) and a trend in
that of alleles (p = 0.10) between alcoholics and control subjects
(Supplementary Table S1).
Two-Way ANCOVAs with group (controls vs. alcoholics)
and PDYN genotype (CC and CT genotypes vs. TT genotype;
subjects with the C, high risk genotype were pooled) as between
factors revealed no additional significant effects in the caudate
nucleus, while uncovered a significant main effects of alcoholism
for PDYN [F(1, 35) = 7.3, p = 0.011], Dyn A [F(1, 39) = 5.3,
p = 0.027] and LER [F(1, 35) = 10.3, p = 0.003], and a trend for
Dyn B [F(1, 36) = 3.84, p = 0.058] in the putamen (Figure 2). A
genotype effect was revealed for Dyn A [F(1, 39)= 4.3, p = 0.044]
and Dyn B [F(1, 36) = 4.2, p = 0.049], but no biologically
meaningful post-hoc differences were significant. A pH effect was
revealed for PDYN [F(1, 35) = 5.6, p = 0.024]. A group ×
smoking interaction was revealed for PDYN [F(1, 35) = 5.6, p =
0.024] and LER [F(1, 35) = 6.5, p = 0.015]. For the combined
CC and CT genotypes post-hoc t-test showed downregulation of
PDYN (2.2-fold; p = 0.051) and LER (2.2-fold; p = 0.018) in
alcoholics.
Thus, PDYN mRNA and MEAP were downregulated in the
caudate nucleus, while PDYN mRNA, Dyn A and LER were
downregulated in the putamen of alcoholics. In the putamen,
the PDYN and LER downregulation was significant in the
subgroup of subjects carrying C, high risk allele of PDYN SNP
rs1997794.
Discussion
Our previous analysis identified upregulation of dynorphins
and κ-opioid receptor in the dorsolateral prefrontal cortex,
orbitofrontal cortex and hippocampus, the cognitive brain
regions involved in control of impulsivity, decision-making, and
learning and memory in human alcoholics (Taqi et al., 2011;
Bazov et al., 2013). In contrast, downregulation of PDYN mRNA
FIGURE 1 | The relative levels of opioid PDYN and PENK mRNA, PDYN
derived Dyn A, Dyn B and Leu-enkephalin-Arg (LER) opioid peptides,
and PENK-derived Met-enkephalin-Arg-Phe (MEAP) opioid peptide in
the caudate nucleus (A) and putamen (B) of alcoholics and controls.
mRNA and peptide levels were normalized to geometric mean of reference
genes andmg of tissue, respectively, and individual data points were corrected
for demographic and tissue co-factors. Data are shown as median, upper and
lower quartiles with the mean value in controls taken as a unit. In controls,
PDYN and PENK mRNA levels before scaling were 0.379 and 0.799 relative
units in caudate nucleus, and 0.677 and 0.947 relative units in putamen,
respectively. In controls, Dyn A, Dyn B, LER, and MEAP before scaling were
396.4, 20.6, 4.5, and 124.8 fmol/mg of tissue in caudate nucleus; and 634.2,
20.0, 7.9, and 53.9 fmol/mg of tissue in putamen, respectively.
and PDYN and PENK derived peptides was demonstrated in
the putamen and caudate nucleus in human alcoholics in the
present study. The brain area specific up- and down-regulation of
PDYN expression may be relevant for different aspects of alcohol
dependence, specifically in the cognitive areas for impairment
of cognitive control of addictive behavior, and in the dorsal
striatum for changes of goal directed behavior and formation of a
compulsive habit, respectively.
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FIGURE 2 | The relative levels of PDYN mRNA and PDYN derived
opioid peptides in the putamen of alcoholic and control subjects
carrying the C, high risk allele (CC and CT genotypes) and the T allele
(TT genotype) of PDYN promoter SNP rs1997794. For details, see
Figure 1 legend. In controls carrying the CC+CT genotype, PDYN mRNA, and
Dyn A, Dyn B, and LER levels before scaling were 0.847 relative units, and
758.5, 24.0, and 9.6 fmol/mg of tissue, respectively.
Study of primates chronically exposed to alcohol
demonstrated increased spine density, enhanced glutamatergic
transmission and increased intrinsic excitability in the putamen
(Cuzon Carlson et al., 2011). The balance of inhibitory/excitatory
transmission was proposed to be shifted toward a persistent
increase in synaptic activation of putamen output as a
consequence of prolonged heavy drinking and relapse.
Downregulation of the dynorphin/κ-opioid receptor system,
which activation is generally characterized by inhibitory
influences on glutamate release and neuronal excitability
(Madamba et al., 1999) is consistent with this statement, and
changes in dynorphins further supports the hypothesis that
alcohol abuse may engage molecular mechanisms of synaptic
plasticity in the dorsal striatal sub-region responsible for habit
formation.
The incentive-sensitization model of addiction postulates
that processing of drug/alcohol cues shifts from ventral to
dorsal striatum during the transition from goal-directed (reward
driven, “wanting”) to habitual and compulsive drug/alcohol use
(Everitt and Robbins, 2005; Vollstadt-Klein et al., 2010). Thus,
compulsive alcohol use is under control of the dorsal striatum.
The N. accumbens mediates motivational and affective functions
while the dorsal striatum encompasses the association and
sensorimotor domains (Siciliano et al., 2015). Chronic ethanol
exposure causes neuroadaptations in the dorsal striatum that
prime for greater control over learning. This shift to striatal
dominance over behavior may be critical for development of
alcohol use disorders (Depoy et al., 2013). The EOS is prominent
in the dorsal striatum. Synthetic and endogenous opioid peptides
induced robust long-term depression of excitatory inputs to the
dorsal striatum (Atwood et al., 2014). MOR, DOR, and KOR
activation produced distinct forms of this depression. KOR-
mediated depression was subregion specific while MOR- and
DOR-mediated effects were specific for input suggesting the
different roles of the three opioid receptors in regulation of
specific components of striatal-based behaviors. Several human
and animal lines of evidence support this statement regarding
alcoholism (Weerts et al., 2011; Nielsen et al., 2012; Ray et al.,
2014; Siciliano et al., 2015). Thus, PET imaging of MOR and
DOR in alcohol-dependent and control subjects demonstrated
the increase in binding potential of the MOR-selective ligand
carfentanil in alcoholics providing evidence of a prominent
role of the MOR in alcohol dependence (Weerts et al., 2011).
Similarly with the molecular differences between alcoholics and
controls identified in the present study, the increase in binding
potential may (i) represent a predisposing risk factor for alcohol
dependence; or (ii) be result of long-term drinking and alcohol
dependence. The binding potential of DOR-selective ligand
methylnaltrindole did not differ between the groups however,
in caudate it positively correlated with recent alcohol drinking
in alcohol-dependent subjects. Thus, the DOR activity may be
affected by recent alcohol drinking history.
The putamen and the precommissural dorsolateral caudate
receive input from the sensorimotor cortex and mediate habitual
drug-taking behaviors that develop after chronic administration.
Understanding the dopaminergic inputs to these striatal regions
may shed light on a role of dopaminergic signaling in alcoholism.
Indeed, voluntary ethanol intake in macaques was found
to induce the KOR supersensitivity and regionally specific
dopaminergic adaptations in the striatum (Siciliano et al., 2015).
Both dopaminergic neurotransmission and KOR sensitivity were
dysregulated in the N. accumbens and dorsolateral caudate
in ethanol drinking animals. Dopamine release and uptake
were increased in the N. accumbens while decreased in the
dorsolateral caudate. In drinking animals both areas developed
KOR sensitivity. The development of KOR sensitivity in the
dorsolateral caudate in macaques (Siciliano et al., 2015) and
increase in MOR binding potential in dorsal striatum in human
alcoholics (Weerts et al., 2011) may develop due to (i) the
elevation in a number of KOR and MOR binding sites; or (ii)
the decrease in synthesis of their endogenous ligands dynorphins
and enkephalins. Our data on the decrease in the levels of these
peptides in the dorsal striatal areas in alcoholics corroborates the
former hypothesis.
We previously demonstrated that the PDYN promoter SNP
rs1997794 associated with alcohol dependence may form non-
canonical AP-1 binding site and influence gene expression in
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human brain (Taqi et al., 2011). In present study, the combined
CC and CT genotypes but not the TT genotype showed
downregulation of both PDYN expression and levels of PDYN
derived LER opioid peptide in the putamen of alcoholics, while
no significant effect of this SNP in the caudate nucleus was
evident. Thus, the impact of rs1997794 on PDYN transcription
may be relevant for brain-area specific adaptive responses of
this gene to alcohol. One may speculate that the upregulation of
delta-FOSB, a constituent of AP-1 that was proposed as a general
mechanism of addiction (Nestler et al., 2001) may contribute
to PDYN regulation if this transcription factor activates PDYN
expression by binding to the T allele of PDYN promoter SNP
(rs1997794). However, this is not apparently the case because
delta-FOSB (i) has not been identified as a subunit of AP-1 in the
human brain where it is formed by the JUND/FOSB heterodimer
(Taqi et al., 2011), (ii) is expressed at negligible levels compared
to FOSB in the human brain, and (iii) is not elevated in the brain
of alcoholics (Watanabe et al., 2009).
We previously reported that in the human anterior cingulate
cortex correlations between PDYN mRNA vs. Dyn A and PDYN
mRNA vs. Dyn B levels were high and significant (R =
0.70–0.85; p < 0.001) whereas those between the respective
mRNA vs. LER and MEAP were substantially lower (Table
3 in Watanabe et al., 2015). In the present study these four
correlations were relatively strong (R = 0.46–0.73; p < 0.001)
for both the caudate nucleus and putamen in both studied
groups of subjects (Supplementary Figure S1). The correlations
differed between brain areas suggesting that enzymes that process
the precursor protein molecules and convert longer opioid
peptides to shorter enkephalins play a role in regulation of
tissue peptide levels (Watanabe et al., 2015). Another factor
that may influence the correlation strength is anatomical
structure; the PDYN and PENK molecules may be processed
to dynorphins and enkephalins either at dendritic location in
the expressing neurons, or in their terminals projecting to
another areas, and this could result in an imbalance between
the mRNA and peptide levels. Consistently, the discrepancy
between changes in the mRNA and peptide levels in the caudate
and putamen of alcoholics may be due to the alterations in (i)
activity of enzymes metabolizing the opioid peptides, and/or
(ii) features of intracellular trafficking of the protein precursor
molecules from the analyzed areas in the pathological human
brain.
As the limitations, the identified associations may be only
applicable (a) to males because no female subjects were analyzed,
and (b) to 83% of analyzed individuals because 10 out of 60
subjects were excluded from analysis. These ten individuals were
identified as overly influential by applying the general statistical
approach (Faraway, 2002). They may represent distinct subject
subgroups in a heterogeneous human population, or may have
clinical and demographic characteristics not described in their
medical history or tissue characteristics altered during tissue
processing. As a general practice, such subjects and also clinical,
biological and technical outliers are excluded from analysis
in molecular human brain studies (Ernst et al., 2009; Shulha
et al., 2012). Consistently, a design of molecular case-control
studies based on analysis of subgroups of subjects but not mean
group effects due to heterogeneity of human population and
etiological heterogeneity of a disease was proven to be successful
in characterization of neuropsychiatric disorders (Sebat et al.,
2007; Walsh et al., 2008; Ernst et al., 2009; Shulha et al., 2012).
Another limitation is the size of the sample and genetic origin
of the individuals analyzed; two group consisted of 24 and
26 subjects, respectively, altogether 50 subjects, all European
descent were included in the final statistical analysis. As always
with human post-mortem molecular investigations, the present
study requires a replication with unrelated set of specimens with
characterized genetic background and identified ethnicity that is
practically challenging. Therefore, this work may be considered
as a pilot study.
Chronic activation of distinct cellular mechanisms by
different addictive substances may induce some sharedmolecular
adaptations - the common molecular syndrome in the brain
regions mediating the lasting nature of the addictive state
(Robison and Nestler, 2011). Downregulation of the dynorphin
system in the dorsal striatum found in cocaine addicts (Yuferov
et al., 2009) and alcoholics (the present study) may be a part of
this shared adaptive mechanism.
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